Table 1 Characteristics of the matched study population.

From: Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study

 

Escalation (n = 164)

Control (n = 328)

p

Age, years

59.5 ± 10.0

58.8 ± 10.6

0.50

Men

123 (75.0)

254 (7.4)

0.62

Risk factor

Hypertension

Diabetes mellitus

Chronic kidney disease

Atrial fibrillation

99 (60.4)

32 (19.5)

8 (4.9)

4 (2.4)

196 (59.8)

68 (20.7)

14 (4.3)

10 (3.0)

0.93

0.77

0.86

0.80

Vascular disease

Coronary artery disease

Ischaemic stroke

Peripheral artery disease

Carotid artery disease

Aortic disease

146 (89.2)

14 (8.4)

1 (0.6)

2 (1.2)

1 (0.6)

296 (90.4)

27 (8.1)

1 (0.3)

3 (0.9)

1 (0.3)

0.93

Acute coronary syndrome

78 (47.6)

156 (47.6)

 > 0.99

Body mass index, kg/m2

25.0 (23.4, 26.9)

24.7 (23.2, 26.9)

0.62

Number of diseased coronary vessels

0

1

2

3

7 (4.3)

69 (42.1)

45 (27.4)

43 (26.2)

12 (3.7)

140 (42.7)

91 (27.7)

85 (25.9)

0.98

LDL-C

   

Baseline, mg/dL

Range, mg/dL

80 (74, 89) (2.07 [1.91, 2.30] mmol/L)

55–98 (1.42–2.53 mmol/L)

79 (73, 88) (2.04 [1.89, 2.28] mmol/L)

55–99 (1.42–2.56 mmol/L)

0.50

Follow-up, mg/dL

Range, mg/dL

65 (54, 73) (1.68 [1.40, 1.89] mmol/L)

35–115 (0.91–2.97 mmol/L)

74 (65, 83) (1.91 [1.68, 2.15] mmol/L)

31–144 (0.80–3.72 mmol/L)

 < 0.001

Percent change

Achievement of < 55 mg/dL (1.4 mmol/L)

-20.9 (-34.3, -6.7)

46 (28.0)

-6.3 (-16.7, 6.8)

20 (6.1)

 < 0.001

 < 0.001

  1. Each value is presented as mean ± standard deviation or number (%); LDL-C, low-density lipoprotein cholesterol.